COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

The FDA has granted priority review to the new drug application (NDA) for gedatolisib, a first-in-class multi-target ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall response rate in treatment-naive patients. Discover the latest ...

DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

Rapid growth in biopharmaceutical R&D, advancements in antibody engineering, and increasing applications in diagnostics and therapeutics drive the market.Austin, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Zymeworks Inc. announced that their bispecific antibody, zanidatamab, has received conditional approval from China's National Medical Products Administration (NMPA) for treating previously treated, ...

Shaji Kumar, MD, Mayo Clinic, focuses on the selection, outcomes, and real-world impact of BCMA-targeted bispecific antibodies for multiple myeloma. He emphasizes the factors influencing choice of ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

Hello, everyone. Good evening and good morning. Thank you for joining HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The ...

Nancy Klauber-DeMore, M.D., led an MUSC team that developed a highly targeted antibody therapy that, by blocking a cancer-driving protein, slowed tumor growth, reduced metastasis and re-energized the ...